Atrium Therapeutics launched with a $270 million financing to advance RNA therapies targeting rare inherited cardiac disorders, MedCity News reported. The spinout emerges from Avidity Biosciences following Novartis’s acquisition of that company, and Atrium’s pipeline is led by two RNA programs with plans to enter the clinic for conditions lacking approved treatments. The sizeable raise signals investor appetite for RNA modalities beyond traditional oligonucleotide classes and highlights continued capital flow into rare‑disease specialty biotech. Atrium’s focus on inherited cardiology disorders addresses high unmet need and could attract strategic partnerships if early clinical data validate preclinical promise. The company’s origin from an acquired unit underscores a growing trend of focused spinouts built around platform assets and disease‑specific pipelines.